Display options
Cite
Hong M, Wang N, Tan HY, et al. MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer Therapy. Cancers (Basel). 2015;7(3):1643-57doi: 10.3390/cancers7030855.
Hong, M., Wang, N., Tan, H. Y., Tsao, S. W., & Feng, Y. (2015). MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer Therapy. Cancers, 7(3), 1643-57. https://doi.org/10.3390/cancers7030855
Hong, Ming, et al. "MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer Therapy." Cancers vol. 7,3 (2015): 1643-57. doi: https://doi.org/10.3390/cancers7030855
Hong M, Wang N, Tan HY, Tsao SW, Feng Y. MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer Therapy. Cancers (Basel). 2015 Aug 24;7(3):1643-57. doi: 10.3390/cancers7030855. PMID: 26305257; PMCID: PMC4586788.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2015 Aug 24;7(3):1643-57. doi: 10.3390/cancers7030855.

MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer Therapy.

Cancers

Ming Hong, Ning Wang, Hor Yue Tan, Sai-Wah Tsao, Yibin Feng

Affiliations

  1. School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. [email protected].
  2. School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. [email protected].
  3. School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. [email protected].
  4. Department of Anatomy, Li KaShing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. [email protected].
  5. School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. [email protected].

PMID: 26305257 PMCID: PMC4586788 DOI: 10.3390/cancers7030855

Abstract

In recent decades Chinese medicine has been used worldwide as a complementary and alternative medicine to treat cancer. Plenty of studies have shown that microRNAs (miRNAs) play fundamental roles in many pathological processes, including cancer, while the anti-cancer mechanisms of Chinese medicinal herbs targeting miRNAs also have been extensively explored. Our previous studies and those of others on Chinese medicinal herbs and miRNAs in various cancer models have provided a possibility of new cancer therapies, for example, up-regulating the expression of miR-23a may activate the positive regulatory network of p53 and miR-23a involved in the mechanism underlying the anti-tumor effect of berberine in hepatocellular carcinoma (HCC). In this review, we survey the role of Chinese medicinal herbal products in regulating miRNAs in cancer and the use of mediating miRNAs for cancer treatment. In addition, the controversial roles of herb-derived exogenous miRNAs in cancer treatment are also discussed. It is expected that targeting miRNAs would provide a novel therapeutic approach in cancer therapy by improving overall response and survival outcomes in cancer treatment, especially when combined with conventional therapeutics and Chinese medicinal herbal products.

Keywords: Chinese medicinal herbs; cancer therapy; exogenous microRNAs; microRNAs

References

  1. Genome Res. 2012 Nov;22(11):2302-14 - PubMed
  2. Oncotarget. 2014 Feb 28;5(4):944-58 - PubMed
  3. Acta Biochim Biophys Sin (Shanghai). 2013 Sep;45(9):756-62 - PubMed
  4. Exp Ther Med. 2011 Jan;2(1):27-32 - PubMed
  5. Dig Dis Sci. 2011 Aug;56(8):2473-81 - PubMed
  6. Cell Res. 2012 Jan;22(1):107-26 - PubMed
  7. BMC Genomics. 2014 Nov 21;15:1010 - PubMed
  8. RNA Biol. 2013 Jul;10(7):1080-6 - PubMed
  9. Leuk Res. 2013 Oct;37(10):1315-21 - PubMed
  10. Cell Biochem Biophys. 2015 Jun;72 (2):325-31 - PubMed
  11. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Jun;18(3):757-61 - PubMed
  12. Clin Transl Oncol. 2013 Sep;15(9):741-6 - PubMed
  13. Nat Cell Biol. 2007 Jun;9(6):654-9 - PubMed
  14. Cell Biochem Funct. 2014 Mar;32(2):209-16 - PubMed
  15. J Tradit Chin Med. 2012 Sep;32(3):299-307 - PubMed
  16. BMC Complement Altern Med. 2014 Jun 05;14:183 - PubMed
  17. Cell. 2005 Jan 14;120(1):15-20 - PubMed
  18. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8 - PubMed
  19. Cell Res. 2008 Oct;18(10):997-1006 - PubMed
  20. Mol Cells. 2014 May;37(5):383-8 - PubMed
  21. Int J Clin Exp Med. 2013;6(1):74-80 - PubMed
  22. Cancer Cell. 2012 Dec 11;22(6):699-701 - PubMed
  23. Cancer Med. 2014 Aug;3(4):878-88 - PubMed
  24. Acta Pharmacol Sin. 2011 Mar;32(3):345-53 - PubMed
  25. Eur J Pharm Sci. 2009 Nov 5;38(4):370-7 - PubMed
  26. Mol Pharmacol. 2012 Apr;81(4):578-86 - PubMed
  27. Pflugers Arch. 2011 Mar;461(3):307-15 - PubMed
  28. Cell Physiol Biochem. 2012;30(3):631-41 - PubMed
  29. PLoS One. 2013 Jul 24;8(7):e68543 - PubMed
  30. Int J Biochem Cell Biol. 2014 Sep;54:286 - PubMed
  31. Toxicol Lett. 2015 May 5;234(3):151-61 - PubMed
  32. Org Biomol Chem. 2015 Feb 28;13(8):2226-38 - PubMed
  33. PLoS One. 2014 Jun 27;9(6):e100124 - PubMed
  34. Cells. 2014 Aug 22;3(3):883-98 - PubMed
  35. Cancers (Basel). 2013 Oct 23;5(4):1306-31 - PubMed
  36. Zhongguo Fei Ai Za Zhi. 2004 Jun 20;7(3):247-9 - PubMed
  37. RNA. 2014 Jun;20(6):754-7 - PubMed
  38. RNA Biol. 2015;12(1):82-91 - PubMed
  39. Evid Based Complement Alternat Med. 2013;2013:590393 - PubMed
  40. Br J Pharmacol. 2011 Jan;162(2):349-64 - PubMed
  41. PLoS One. 2012;7(1):e29770 - PubMed
  42. Clin Cancer Res. 2013 Jun 15;19(12):3130-42 - PubMed
  43. Complement Ther Med. 2014 Jun;22(3):567-79 - PubMed
  44. J Tradit Chin Med. 2011 Mar;31(1):10-6 - PubMed
  45. Chemotherapy. 2014;60(2):112-8 - PubMed
  46. Cancer Res. 2010 Feb 15;70(4):1486-95 - PubMed
  47. PLoS One. 2013 Aug 07;8(8):e71130 - PubMed
  48. Nat Biotechnol. 2013 Nov;31(11):965-7 - PubMed
  49. Bioinformation. 2013 Jul 17;9(13):659-60 - PubMed
  50. Am J Transl Res. 2010 Oct 23;3(1):90-9 - PubMed
  51. BMC Cancer. 2013 Sep 17;13:421 - PubMed
  52. Tumour Biol. 2014 Nov;35(11):10645-63 - PubMed
  53. Chin J Integr Med. 2014 Jul;20(7):496-502 - PubMed
  54. Zhongguo Zhong Yao Za Zhi. 2009 Sep;34(18):2405-9 - PubMed
  55. Front Cell Neurosci. 2013 Aug 27;7:133 - PubMed
  56. Chin J Cancer. 2014 Dec;33(12):620-4 - PubMed
  57. Mol Med Rep. 2015 Jul;12 (1):885-94 - PubMed
  58. Oncogene. 2013 Jan 24;32(4):431-43 - PubMed
  59. Zhongguo Zhong Yao Za Zhi. 2011 May;36(9):1231-4 - PubMed
  60. Mol Cell Proteomics. 2015 Feb;14 (2):316-28 - PubMed
  61. Mol Cancer Ther. 2014 Jan;13(1):239-48 - PubMed
  62. Oncotarget. 2015 Feb 20;6(5):2736-53 - PubMed
  63. Genome Res. 2010 May;20(5):589-99 - PubMed
  64. Carcinogenesis. 2015 Mar;36(3):355-67 - PubMed
  65. Nat Biotechnol. 2013 Nov;31(11):967-9 - PubMed
  66. J Cancer Res Ther. 2014 Aug;10 Suppl 1:52-5 - PubMed
  67. Br J Pharmacol. 2011 Jan;162(2):346-8 - PubMed
  68. Biochim Biophys Acta. 2014 Sep;1839(9):849-57 - PubMed
  69. Technol Cancer Res Treat. 2015 Dec;14(6):747-55 - PubMed
  70. BMC Cancer. 2012 Nov 20;12 :534 - PubMed
  71. Asian Pac J Cancer Prev. 2011;12(9):2233-6 - PubMed
  72. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 - PubMed
  73. Br J Cancer. 2014 Mar 18;110(6):1645-54 - PubMed

Publication Types